JOP20190155A1 - مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم - Google Patents

مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم

Info

Publication number
JOP20190155A1
JOP20190155A1 JOP/2019/0155A JOP20190155A JOP20190155A1 JO P20190155 A1 JOP20190155 A1 JO P20190155A1 JO P20190155 A JOP20190155 A JO P20190155A JO P20190155 A1 JOP20190155 A1 JO P20190155A1
Authority
JO
Jordan
Prior art keywords
drug conjugates
stem cells
hematopoietic stem
antibody drug
antibody
Prior art date
Application number
JOP/2019/0155A
Other languages
English (en)
Inventor
Siew Ho Schleyer
Si Tuen Lee-Hoeflich
Tetsuo Uno
Kathrin Tissot
Susan E Cellitti
Ben Wen
Yunho Jin
Michael P Cooke
Matthew Burger
Anthony E Boitano
Bernhard Hubert Geierstanger
Hongngoc Thi Pham
Catrin Finner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190155A1 publication Critical patent/JOP20190155A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

يتعلق الاختراع الحالي بمترافقات عقار جسم مضاد، حيث جسم مضاد أو شظية جسم مضاد التي ترتبط بشكل محدد بـ cKIT بشري ترتبط بجزء عقار، اختيارياً من خلال رابط. يقدم الاختراع الحالي أيضاً تركيبات صيدلانية تشتمل على مترافقات عقار الجسم المضاد؛ وطرق لتحضير واستخدام تلك التركيبات الصيدلانية لإزالة خلايا جذعية مكونة للدم في مريض بحاجة لها. الشكل 1
JOP/2019/0155A 2016-12-21 2017-06-16 مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم JOP20190155A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437622P 2016-12-21 2016-12-21
US201762520854P 2017-06-16 2017-06-16

Publications (1)

Publication Number Publication Date
JOP20190155A1 true JOP20190155A1 (ar) 2019-06-23

Family

ID=60957364

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0155A JOP20190155A1 (ar) 2016-12-21 2017-06-16 مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم

Country Status (23)

Country Link
US (2) US11357864B2 (ar)
EP (1) EP3558389A1 (ar)
JP (2) JP7181203B2 (ar)
KR (1) KR20190099238A (ar)
CN (2) CN117653740A (ar)
AU (1) AU2017383458C1 (ar)
BR (1) BR112019012483A2 (ar)
CA (1) CA3045592A1 (ar)
CL (1) CL2019001745A1 (ar)
CO (1) CO2019006455A2 (ar)
CR (1) CR20190296A (ar)
CU (1) CU24644B1 (ar)
EA (1) EA201991526A1 (ar)
EC (1) ECSP19044625A (ar)
IL (2) IL300567A (ar)
JO (1) JOP20190155A1 (ar)
MA (1) MA47231A (ar)
MX (1) MX2019007582A (ar)
MY (1) MY193985A (ar)
PE (1) PE20191539A1 (ar)
PH (1) PH12019501330A1 (ar)
TW (2) TWI778994B (ar)
WO (1) WO2018116178A1 (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3452492A1 (en) 2016-05-05 2019-03-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
CN109661400A (zh) * 2016-06-17 2019-04-19 美真达治疗公司 用于耗尽cd117+细胞的组合物和方法
JP2021526525A (ja) * 2018-06-07 2021-10-07 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
UY38265A (es) * 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
CN112739339A (zh) * 2018-07-23 2021-04-30 美真达治疗公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
AU2019311077A1 (en) * 2018-07-23 2021-02-25 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
KR20210081393A (ko) * 2018-10-23 2021-07-01 마젠타 테라퓨틱스 인코포레이티드 Fc 침묵 항체 약물 컨쥬게이트(ADC) 및 이의 용도
WO2020089811A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
KR20210094610A (ko) * 2018-11-26 2021-07-29 포티 세븐, 인코포레이티드 c-Kit에 대한 인간화 항체
EP3894387A4 (en) * 2018-12-12 2023-07-19 Levim Biotech LLP ACYLATION PROCESSES FOR THE PRODUCTION OF N-SUBSTITUTED PEPTIDES
AU2020289360A1 (en) * 2019-06-04 2022-01-20 Magenta Therapeutics, Inc. Methods and compositions for treating autoimmune diseases
WO2021022678A1 (zh) * 2019-08-07 2021-02-11 烟台迈百瑞国际生物医药股份有限公司 一种抗体药物偶联物及其应用
CN116183899B (zh) * 2023-04-28 2023-06-30 天津市协和医药科技集团有限公司 一种吖啶酯标记抗体保存液的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ES2181673T3 (es) 1991-05-01 2003-03-01 Jackson H M Found Military Med Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JP2000506165A (ja) 1996-03-04 2000-05-23 ザ ペン ステイト リサーチ ファウンデーション 細胞インターナリゼーションを増強するための物質および方法
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0954282B1 (en) 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
ATE386802T1 (de) 1997-06-12 2008-03-15 Novartis Int Pharm Ltd Künstliche antikörperpolypeptide
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
AU2003208415B2 (en) * 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
ATE475673T1 (de) 2003-03-24 2010-08-15 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
WO2008067115A2 (en) 2006-11-03 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
BR112015001459B1 (pt) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
CN115925957A (zh) 2013-02-08 2023-04-07 Irm责任有限公司 用于修饰抗体以制备免疫缀合物的特定位点
CA2903772A1 (en) * 2013-03-15 2014-09-25 Novartis Ag Antibody drug conjugates
AU2015229463A1 (en) * 2014-03-12 2016-09-15 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
EA201692530A1 (ru) 2014-06-13 2017-07-31 Новартис Аг Цитотоксические пептиды и их конъюгаты
WO2016020791A1 (en) * 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US9938323B2 (en) 2014-11-06 2018-04-10 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
CN108137648A (zh) * 2015-04-06 2018-06-08 哈佛学院校长同事会 用于非清髓性预处理的组合物和方法
US20190194315A1 (en) * 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CN109661400A (zh) * 2016-06-17 2019-04-19 美真达治疗公司 用于耗尽cd117+细胞的组合物和方法

Also Published As

Publication number Publication date
AU2017383458C1 (en) 2021-08-12
MA47231A (fr) 2019-10-30
JP2020504112A (ja) 2020-02-06
US20220305134A1 (en) 2022-09-29
WO2018116178A1 (en) 2018-06-28
CU20190061A7 (es) 2020-03-04
JP7181203B2 (ja) 2022-11-30
CO2019006455A2 (es) 2019-06-28
CN117653740A (zh) 2024-03-08
BR112019012483A2 (pt) 2020-04-14
CR20190296A (es) 2019-09-13
IL300567A (en) 2023-04-01
PH12019501330A1 (en) 2020-03-02
US20190321483A1 (en) 2019-10-24
PE20191539A1 (es) 2019-10-23
IL267478B1 (en) 2023-03-01
AU2017383458B2 (en) 2021-04-29
MX2019007582A (es) 2019-09-06
CL2019001745A1 (es) 2019-09-13
JP2023015080A (ja) 2023-01-31
ECSP19044625A (es) 2019-06-30
TW201828991A (zh) 2018-08-16
CU24644B1 (es) 2023-02-13
CA3045592A1 (en) 2018-06-28
EA201991526A1 (ru) 2020-01-24
CN110099697B (zh) 2023-11-28
TWI778994B (zh) 2022-10-01
AU2017383458A1 (en) 2019-06-13
RU2019122794A (ru) 2021-01-22
KR20190099238A (ko) 2019-08-26
RU2019122794A3 (ar) 2021-10-12
IL267478B2 (en) 2023-07-01
CN110099697A (zh) 2019-08-06
MY193985A (en) 2022-11-04
US11357864B2 (en) 2022-06-14
IL267478A (en) 2019-08-29
EP3558389A1 (en) 2019-10-30
TW202300524A (zh) 2023-01-01

Similar Documents

Publication Publication Date Title
PH12019501330A1 (en) Antibody drug conjugates for ablating hematopoietic stem cells
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
PH12018501554A1 (en) Ror1 antibody compositions and related methods
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
MX2017002600A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
PH12016501995A1 (en) Tubulysin derivatives
AR095666A1 (es) Conjugados de fármacos con anticuerpos
MY169147A (en) Drug-protein conjugates
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
CR20200206A (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
WO2019244082A3 (en) Antibody drug conjugates for ablating hematopoietic stem cells
PH12016500822A1 (en) Anti-efna4 antibody-drug conjugates
EA201991251A1 (ru) Пептидсодержащие линкеры для конъюгатов антитело-лекарственное средство